Skip to content
Shingles Science Image Shingles Science Image






HIV, human immunodeficiency virus.



  Human Immunodeficiency Virus (HIV)
People living withHIV19
Autologous Haematopoietic Stem Cell Transplant (auHSCT) Post-autologous5 Haematological Malignancies
While on immunosuppressive chemotherapy7
Renal Transplants
Post-renal transplant20
Solid Tumour
Solid tumour malignancies while on immunosuppressive chemotherapy21
Trial NCT01165203* NCT01610414 NCT01767467 NCT02058589 NCT01798056
Phases Phase 1/2a
Phase 3
Phase 3
Phase 3
Phase 3
Trial type Placebo-controlled, ≥18 years of age
Efficacy Reactogenicity/
Month 0, 2, 6
(3 doses)
Month 0, 1–2
  Click here for further information on NCT01165203 Click here for further information on NCT01610414 Click here for further information on NCT01767467 Click here for further information on NCT02058589 Click here for further information on NCT01798056

*RZV was studied in a Phase 1/2a trial in HIV patients; a phase 1/2, randomised, observer-blind, placebo-controlled study was previously conducted to assess safety and immunogenicity of two formulations of RZV in adults with multiple myeloma, non-Hodgkin lymphoma (B- or T-cell), Hodgkin lymphoma, or acute myeloid leukaemia who had undergone autologous haematopoietic stem-cell transplant 50 to 70 days earlier; §efficacy was evaluated in a post hoc analysis.7

References: 5. Bastidas A, et al. JAMA. 2019;322(2):123–133; 7. Dagnew AF, et al. Lancet Infect Dis. 2019;19(9):988–1000; 19. Berkowitz EM, et al. J Infect Dis. 2015;211(8):1279–1287; 20. Vink P, et al. Clin Infect Dis. 2020;70(2):181–190; 21. Vink P, et al. Cancer. 2019;125(8):1301–1312.

auHSCT, autologous haematopoietic stem cell transplant; HIV, human immunodeficiency virus; RZV, recombinant zoster vaccine.


auHSCT患者では68.2%、血液悪性腫瘍患者ではPost-hoc Analysisにおいて87.2%の有効性が示されました。固形がん患者や腎移植患者に対する有効性データはありませんが、細胞性免疫反応はauHSCT患者や血液悪性腫瘍患者における試験結果と同等であり、同様の臨床的ベネフィットが示されました5,7,18-21


AE, adverse event; ART, anti-retroviral therapy; ATP, according to protocol; BCL, B-cell lymphoma; CLL, chronic lymphocytic leukaemia; CMI, cell-mediated immunity; gE, glycoprotein E; GI, gastrointestinal; GMC, geometric mean concentration; HIV, human immunodeficiency virus; IQR, interquartile range; LL, lower limit; Mo, month; mTVC, modified total vaccinated cohort; pIMD, potential immune-mediated disease; PHN, post-herpetic neuralgia; Pre, pre-vaccination; Q, quartile; RZV, recombinant zoster vaccine; SAE, serious adverse event; TVC, total vaccinated cohort; UL, upper limit; VE, vaccine efficacy; VRR, vaccine response rate; YOA, years of age


  1. Chen SY, et al. Infection. 2014;42(2):325–334.
  2. Zhang D, et al. Adv Ther. 2017;34(7):1610–1621.
  3. Sahoo F, et al. Biol Blood Marrow Transplant. 2017;23(3):505–511.
  4. Winston DJ, et al. Lancet. 2018;391(10135):2116–2127.
  5. Bastidas A, et al. JAMA. 2019;322(2):123–133.
  6. Habel LA, et al. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82–90.
  7. Dagnew AF, et al. Lancet Infect Dis. 2019;19(9):988–1000.
  8. Koo S, et al. Transpl Infect Dis. 2014;16(1):17–25.
  9. Pergam SA, et al. Transpl Infect Dis. 2011;13(1):15–23.
  10. Arness T, et al. Transpl Infect Dis. 2008;10(4):260–268.
  11. Mao J, et al. Medicine (Baltimore). 2017;96(48):e8746.
  12. Tseng HF, et al. Clin Infect Dis. 2014;59(7):913–919.
  13. Blank LJ, et al. J Acquir Immune Defic Syndr. 2012;61(2):203–207.
  14. Chakravarty EF. Rheum Dis Clin North Am. 2017;43(1):111–121.
  15. Veetil BM, et al. Arthritis Care Res (Hoboken). 2013;65(6):854–861.
  16. Khan N, et al. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927.
  17. Johnson BH, et al. BMC Infect Dis. 2015;15:502.
  18. Dagnew AF, et al. Hum Vaccin Immunother. 2021;17(11):4132–4143.
  19. Berkowitz EM, et al. J Infect Dis. 2015;211(8):1279–1287.
  20. Vink P, et al. Clin Infect Dis. 2020;70(2):181–190.
  21. Vink P, et al. Cancer. 2019;125(8):1301–1312.
  22. de la Serna J, et al. Efficacy and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients 18 Years of Age or Older: First Results of the Phase 3 Randomized, Placebo-Controlled ZOE-HSCT Clinical Trial. Presented at BMT Tandem Meeting; 25th February 2018; Salt Lake City, UT, USA.
  23. NCT01610414. Available at: (accessed May 2023).
  24. Zoster-002 Clinical Study Report 115523. Available at: (accessed May 2023).
  25. Zoster-039 Clinical Study Report 116428. Available at: (accessed May 2023).
  26. NCT01798056. Available at: (accessed May 2023).
  27. Zoster-028 Clinical Study Report 116427. Available at: (accessed May 2023).
  28. Vink P. Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical Trial. Poster #1349. Presented at IDWeek; 4–8 October, 2017; San Diego, CA, USA.
  29. NCT02058589. Available at: (accessed May 2023).
  30. Vink P, et al. Open Forum Infect Dis. 2018;5(suppl 1):S744–S745.
  31. Zoster-041 Clinical Study Report 116886. Available at: (accessed May 2023).
  32. Zoster-015 Clinical Study Report 112673. Available at: (accessed May 2023).

NX-JP-SGX-WCNT-230008 | October 2023